FDA Clears Clinical Trial for CAR T-Cell Therapy in Advanced Colorectal Cancer, Expanding Solid Tumor Reach

September 13, 2026

University of Colorado Anschutz USA

Overview

The U.S. Food and Drug Administration (FDA) has authorized researchers at the University of Colorado Anschutz to conduct a clinical trial for CAR T-cell therapy targeting advanced colorectal cancer in adults and pediatric solid tumors resistant to standard treatments. This approval represents a pivotal expansion of CAR T-cell therapy, traditionally successful in blood cancers, into challenging solid tumor indications like colorectal cancer, marking a significant step forward in oncology.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has granted approval for researchers at the University of Colorado Anschutz to initiate a Phase 1 clinical trial of CAR T-cell therapy for adult patients with advanced colorectal cancer and pediatric patients with solid tumors who have exhausted standard treatment options. This authorization marks a critical milestone in extending the application of CAR T-cell therapies, which have demonstrated remarkable success primarily in hematological malignancies, to notoriously difficult-to-treat solid tumors.

Technical / Clinical Details

The CAR T-cell therapy to be evaluated in this clinical trial involves collecting a patient’s own T-cells and genetically modifying them to recognize and target specific molecular markers on cancer cells. This engineering imbues the modified T-cells with the ability to selectively attack tumor cells. Colorectal cancer is a leading cause of cancer-related mortality worldwide, with a grim prognosis in its advanced stages. To overcome previous challenges faced by CAR T-cell therapies in solid tumors—such as the immunosuppressive tumor microenvironment and lack of uniform target antigens—this trial may employ novel target antigens or CAR construct designs. For pediatric solid cancers, recurrent or progressive cases also present limited treatment options, intensifying the hope for new therapies.

Background & Context

CAR T-cell therapy has established itself as a transformative treatment for blood cancers like leukemia and lymphoma, achieving high complete response rates and enabling long-term survival. However, in solid tumors, the efficacy of CAR T-cell therapy has been limited due to barriers such as complex tumor microenvironments, immunosuppressive mechanisms, and antigenic heterogeneity. This FDA approval represents a crucial step in overcoming these barriers and validating the safety and efficacy of CAR T-cell therapy in solid tumors, thereby opening new frontiers in cancer treatment research.

Strategic Significance & Outlook

The primary objectives of this Phase 1 clinical trial are to assess the safety and tolerability of the treatment, alongside exploring initial efficacy signals. If successful, it would not only offer new therapeutic hope for patients with colorectal cancer and other pediatric solid cancers but also provide invaluable insights for expanding the utility of CAR T-cell therapies. Potentially, this could accelerate the deployment of CAR T-cell therapies to a broader range of solid tumor indications in the future.

Source: https://news.cuanschutz.edu/news-stories/your-blog-fda-clears-clinical-trial-using-car-t-cells-to-fight-colorectal-cancer

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.